Aptevo Therapeutics Profit Margin

Aptevo Therapeutics posts a profit margin of 13390.0% as of June 2026. That is above the Healthcare sector average of 13.89%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a profit margin near 13.89% is typical. Aptevo Therapeutics's 13390.0% is higher that level. That is roughly 96299.2% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Aptevo Therapeutics's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 13390.0% as of June 2026; use YoY and peer views to separate noise from signal.

Context for APVO's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.89%), and (3) consistency with growth and profitability. This page covers the first two; Aptevo Therapeutics's other metric pages and overview cover the third.

Judging Aptevo Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in profit margin easier to interpret. Start with 13390.0% here, then scan peer and history charts to see if the gap is persistent.